|
- Imetelstat Sodium - NCI - National Cancer Institute
Imetelstat sodium works by blocking the activity of an enzyme called telomerase, which is found at high levels in cells that divide rapidly, including cancer cells Blocking this enzyme keeps cancer cells from dividing and causes them to die Imetelstat sodium is a type of targeted therapy called an enzyme inhibitor
- Imetelstat, a novel, first‐in‐class telomerase inhibitor: Mechanism of . . .
Most cancers and neoplastic progenitor cells have elevated telomerase activity and preservation of telomeres that promote cellular immortality, making telomerase a rational target for the treatment of cancer Imetelstat is a first‐in‐class, 13‐mer
- Oncology Drug Reference Sheet: Imetelstat - ons. org
In June 2024, imetelstat (Rytelo™) became the first telomerase inhibitor approved by the U S Food and Drug Administration (FDA) Imetelstat treats low- to intermediate-risk myelodysplastic syndromes in adults with transfusion-dependent anemia
- Why RYTELO (imetelstat) | RYTELOHCP
INDICATION RYTELO® (imetelstat) is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA)
- Imetelstat (Rytelo™) - OncoLink
Imetelstat (Rytelo™) is a telomerase inhibitor How To Take Imetelstat Imetelstat is given intravenously (into a vein) The amount given and schedule are based on your size You will have your labs checked before each dose The results of your labs help guide your treatment plan You will be given diphenhydramine (Benadryl) and hydrocortisone (steroid) before your infusion to help lessen an
- Clinical - Imetelstat
Imetelstat for treatment of myelofibrosis J Mascarenhas et al (tandfonline com, 10 Dec 2016) Areas covered: The pre-clinical rationale for the use of the telomerase inhibitor, imetelstat, in patients with advanced MF and essential thrombocythemia (ET) will be reviewed as well the results of the initial clinical trials with this agent
- Rytelo: Uses, Dosage, Side Effects, Warnings - Drugs. com
Rytelo (imetelstat) is an injectable telomerase inhibitor that may be used to treat adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia
- Geron Announces FDA Approval of RYTELO™ (imetelstat), a . . . - Geron Corp
About Geron Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer Our first-in-class telomerase inhibitor RYTELO™ (imetelstat) is FDA-approved for the treatment of adult patients with lower-risk MDS with transfusion dependent anemia
|
|
|